ITMI950380A1 - Pharmaceutical compositions containing an anti-inflammatory agent and an antimicrobial agent. - Google Patents

Abstract

Pharmaceutical compositions and compositions for oral hygiene containing an anti-inflammatory agent and an antimicrobial agent, with an improved antimicrobial activity.

Description

Description of the industrial invention entitled: "PHARMACEUTICAL COMPOSITIONS CONTAINING AN ANTI-INFLAMMATORY AGENT AND AN ANTIMICROBIAL AGENT ·

The present invention relates to pharmaceutical compositions and compositions for oral hygiene containing an anti-inflammatory agent and an antimicrobial agent, and having improved antimicrobial activity.

Benzidamine is a well-known non-steroidal anti-inflammatory agent. The preparation of benzydamine is described in US patent No.

3318905. The use of benzydamine in mouthwashes has been proposed, for example in Current Therapeutical Research, Clin. Exp., 1978, 23/6, (734-745).

Pathogenic bacteria of the oral cavity are involved in numerous diseases of the oral cavity, including plaque, gingivitis and periodontal diseases. In addition, pathogenic fungi, such as candida, may also be present in the oral cavity and other body cavities and cause pathological states, such as aphthous stomatitis, which require treatment.

Agents proposed in the past as antibacterials include: cationic compounds such as chlorhexidine, alexidine, hexetidine and cetylpyridinium chloride and non-cationic compounds such as triclosan. Some of these antibacterial agents are also effective as arrtimycotic agents.

In many cases, a single antimicrobial agent does not have a broad enough spectrum of activity to adequately control a wide variety of pathogenic microorganisms that can be found in the oral cavity. The combination of different antimicrobial agents is not always effective, since the presence of one can antagonize the activity of the other.

It has now surprisingly been found that benzydamine can be advantageously associated with an antimicrobial agent, without compromising the activity of benzydamine and with an increase in the activity of the antimicrobial agent, so as to provide an effective antiseptic and analgesic treatment for microbial infections.

Accordingly, the present invention provides a pharmaceutical composition, particularly an oral hygiene composition, which comprises an anti-inflammatory amount of benzydamine or a benzidamine salt, an antimicrobically effective amount of a cetylpyridinium chloride and a pharmaceutically friendly vehicle or excipient. or orally acceptable.

Benzidamine can be used in the form of a pharmaceutically acceptable salt thereof, for example as benzydamine hydrochloride.

Suitable antimicrobial agents may have antibacterial or antifungal activity or a combination of antibacterial and antifungal activity.

Cetylpyridinium chloride is active against both bacteria and fungi. In many cases it has been found that the concentration of the antimicrobial agent required for the antifungal activity is lower than that required for the antibacterial activity. Therefore, lower levels of such antimicrobial agents may be incorporated into the compositions of the present invention if it is desired that such antimicrobial agents be present primarily to provide anti-Candida activity.

In a preferred embodiment, the present invention provides a composition which comprises an anti-inflammatory amount of benzydamine, preferably as benzidaimine hydrochloride, and an antibacterial amount of cetylpyridinium chloride.

In another preferred form, cetylpyridinium chloride also exerts anti-plaque activity. In addition, the composition may comprise an anti-plaque agent such as chlorhexidine, triclosan, histatin or nisin (particularly in the purified form available as ambicin N from Applied Microbiology Ine., New York).

A composition of the invention may contain benzydamine and the antimicrobial agent in the ratio (by weight) of 10: 1 to 1:10, suitably 5: 1 to 1: 5 and typically about 3: 1 to about 1: 3.

The amount of benzidamine present in the composition of the invention is such as to reach, after administration, a sufficient level to have an effective and desirable anti-inflammatory effect and to enhance the activity of the antimicrobial agent. Due to the effect of benzydamine in the composition of the invention, the antimicrobial agent may be employed in an amount less than that conventionally used to produce effective or desirable antimicrobial activity. Conventional knowledge of the use of these materials in therapy will provide a useful guide to the appropriate amounts to be employed in the present invention, in association with routine tests as described in the Biological Assessment annexed to this specification.

A particularly preferred composition contains benzydamine hydrochloride and cetylpyridinium chloride in a ratio of about 3: 1. This composition shows a synergistic effect against a wide variety of organisms such as Propionibacterium acnes, Capnocytophaga gingivalis, Bacteroides oralis and Candida albicans.

The composition of the invention can be formulated for topical application, for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, sprays, tampons, mouthwashes, impregnated gauze, sutures and aerosols, and may contain suitable conventional additives , including, for example, preservatives, solvents to facilitate drug penetration and emollients in ointments and creams. Such topical formulations may also contain conventional compatible carriers, e.g. bases for creams or ointments and ethanol or oleic alcohol for lotions. Such vehicles may constitute from about 1 to about 98% by weight of the formulation; more commonly they are used up to 80% of the weight of the formulation.

For administration to human patients, the daily dosage level of each active agent is expected to be 0.01 to 10 mg / kg, typically about 1 mg / kg. The physician in each case will determine the actual dosage and the most appropriate interval of administration for the individual patient, depending on the age, weight and response of the particular patient. The foregoing dosages are exemplary of the average case. There may, of course, be individual cases in which higher or lower dosages are required and such dosages are also included within the scope of the invention.

With the indicated dose range, no harmful toxicological effects such as to preclude their administration to patients will be observed with the compounds of the invention.

For use in oral hygiene, the compositions of the present invention can be provided in any of the presentations normally employed for such products, for example, toothpastes or powders, abrasive and non-abrasive gels, mouthwashes, gargles, irrigation solutions. , buccal sprays and presentations suitable for chewing or sucking by the user, such as skirts, pads and tablets. The components for the pharmaceutically acceptable carrier or excipient will be selected according to the particular type of presentation desired. These compositions will contain suitable formulation agents such as abrasives, surfactants, humectants, thickeners, flavorings, sweeteners, opacifiers, preservatives and water, selected from those conventionally used in compositions for oral hygiene and compatible with benzydamine and the antimicrobial agents described above. .

Suitable surfactants for use in the compositions according to the present invention include, for example, anionic, nonionic, cationic and amphoteric surfactants or mixtures thereof. It will be understood that in order to ensure that the efficacy of a cationic antimicrobial agent is not substantially diminished, compatible components will be selected for inclusion in the orally acceptable carrier or excipient.

Consequently, the skilled person will readily understand that, when necessary, anionic species may not be indicated, as such species can cause the inactivation of a cationic antimicrobial agent through the formation of an insoluble precipitate with it. Therefore, anionic surfactants and anionic thickening agents will preferably be avoided in favor of the corresponding non-anionic agents such as nonionic, cationic or amphoteric surfactants and nonionic thickening agents.

When employable, suitable anionic surfactants include

(C12-18) alkylsulfates of alkali metals, for example sodium laurylsoliate, and N-acylsarcosinates and N-acyltaurines in which the acyl group has 12 to 16 carbon atoms, for example, alkali metal salts of N-lauroyl, N -miristcil and N-palmitoylsarcosin.

Suitable non-ionic surfactants include, for example, polyethoxylated esters of sorbitol, in particular polyethoxylated nonoesters of sorbitol, for example, PSG (40) sorbitan di-isostearate and products marketed under the name "Twreen" by ICI; polycondensates of ethylene oxide and propylene oxide (poloxamers) for example products marketed under the name "Pluronic" by BASF-Wyandotte; propylene glycol condensates; polyethoxylated hydrogenated castor oil, for example, cremophor; and fatty esters of sorbitan.

Suitable amphoteric surfactants include, for example, long-chain derivatives of imidazoline, such as the product marketed under the name "Miranol C2M" by Miranol; long-chain alkylbetaines, such as the product marketed under the name "Empigen BB" by Albright Wilson, and long-chain alkyl amidoalkyl betaines, such as cocamidopropylbetaine and their mixtures.

Suitable cationic surfactants will include the salt with ethyl-N-coaoyl-L-arginate D, L-2-pyrrolidon-5-carboxylic acid, marketed under the name CAE by Ajinomoto Co. Ine. and cocamidopropyl PG dimonium chloride phosphate and lauramidopropyl PG dimonium chloride phosphate, available under the names Monaquat PTC and Monaquat PTL, respectively from Mona Corporation.

Advantageously, the surfactant is present in the range from 0.005 to 20%, preferably from 0.1 to 10%, more preferably from 0.1 to 5% on the weight of the toothpaste.

Suitable thickening agents include, for example, non-ionic thickening agents such as, for example, (C1-6) alkylcellulose ethers, for example methylcellulose; hydroxy ethers (C1-6) alkylcellulose, for example hydroxyethylcellulose and hydroxypropylcellulose; ethers of (C1-6) alkylcellulose modified with (C2-6) alkylene oxides, for example hydroxypropylmethylcellulose; and their mixtures. Other thickening agents can also be used, such as natural and synthetic germ or rubber-like materials such as Irish Moss, tragacanth, sodium carboxymethylcellulose, polyvinylpyrrolidone, starch and silica thickeners.

Advantageously, the thickening agent is present in the range from 0.01 to 30%, preferably from 0.1 to 15%, more preferably from 1 to 5% on the weight of the composition.

Suitable humectants for use in the compositions of the invention include, for example, glycerin, sorbitol, propylene glycol or polyethylene glycol or mixtures thereof; the humectant can be present in the range from 5 to 70%, preferably from 5 to 30%, more preferably from 10 to 30% on the weight of the composition.

Abrasives suitable for use in the toothpaste compositions of the present invention include calcium carbonate, calcium phosphates, calcium pyrophosphate, insoluble sodium metaphosphate,

sodium aluminosilicate, alumina, hydrated aluminas, zinc orthophosphate, plastic particles and silica, of which silica is the preferred abrasive.

Suitable silicas include natural amorphous silicas, such as, for example, diatomaceous earth, and synthetic amorphous silicas, such as precipitated silicas and silica gels, including silica xerogels. Suitable silica xerogels are disclosed in US 3,538,230. Suitable grades of precipitated silicas have BET surface areas in the range from 20 to 300, preferably from 20 to 100 m / g and average agglomerate sizes in the range from 2 to 50, preferably from 5 to 30m.

Suitable precipitated silicas and silica xerogels are those marketed under the names Sident and Syloblanc, by Degùssa and WR Grace Corporation Davison Chemical Division, respectively.

Advantageously, silica is a "low anion" silica. As used herein, the term "low anion" silica refers to those silicas in which the anionic impurities, such as sodium sulfate and sodium silicate, which normally derive from the preparation process, are kept to a minimum, through careful process control. of preparation. "Low anion" silicas suitably have less than 1%, preferably less than 0.5% and advantageously less than 0.25% by weight of anionic impurities.

Suitable "low anion" silicas are described in EP 0368130 (Procter & Gamble), EP 0315503 and EP 0396459 (Rhone-Poulenc) and WO 90/05113 (J.M. Huber Corp). Alternatively, commercially available grades of silica with ionic purities can be made suitable by washing with deionized water. Conductivity measurements on the water after washing can be used to monitor the effectiveness of the wash. Conveniently, the conductivity of the water after washing is reduced to less than 200 μ Siemens / cm. Suitable "low anion" silicas include grade RP93 available from Rhone-Poulenc.

Conveniently, the compositions will have from 5 to 80%, preferably from 10 to 60% by weight of the abrasive.

Suitable mouthwash formulations will have an aqueous base comprising water or aqueous ethanol and optionally another liquid such as glycerin or propylene glycol. A surfactant may also be included to improve the organoleptic properties of the composition. The compositions in the form of mouthwash can be provided in a ready-to-use form, such as a concentrated solution, to be diluted by the user immediately before use; or in solid form, such as a tablet or sachet to be dissolved immediately before use. The tablets can be conveniently prepared using xylitol and / or sorbitol as the main ingredient. The sachets and tablets can be formulated to provide, after dissolution, a non-sparkling mouthwash or, by incorporation of a suitable effervescent couple, for example, sodium carbonate / bicarbonate and citric acid, an effervescent mouthwash.

The oral hygiene compositions of the present invention may usefully also comprise an anticary agent, for example a source of fluoride ions, such as an alkali metal or ammine fluoride salt, for example sodium fluoride, tin (II) fluoride. Alternatively, the source of hyene fluoride can be an alkali metal monofluorophosphate salt, for example sodium monofluorophasfate, optionally used in combination with an agent such as calcium glycerophosphate, known to increase the activity of monofluorophosphate (GB 1384375, Beecham Group). Conveniently, the composition will comprise between 250 and 2500 ppm, preferably between 500 and 1500 ppm of fluoride ions.

The oral hygiene compositions of the present invention may also comprise other active agents conventionally employed in oral hygiene compositions, for example:

an anti-plaque agent other than those already mentioned; an anti-tartar agent, such as an alkali metal tetra- or di-pyrophosphate or a mixture thereof, an alkali metal tripolyphosphate or an azacycloheptane diphosphonate salt; or a desensitizing agent, such as strontium acetate, strontium chloride or a potassium salt, such as potassium nitrate, potassium chloride or potassium citrate.

Such agents will be included in amounts such as to provide the desired therapeutic effect.

The oral hygiene compositions according to the present invention will have an orally acceptable pH, typically between about pH 4 and 10.

The compositions for oral hygiene according to the present invention can be prepared by mixing the ingredients in suitable relative quantities in any convenient sequence and then, if necessary, adjusting the pH to give the final desired value.

The compositions of this invention can be used in the therapy or prophylaxis of microbial infections accompanied by irritation, such as vaginal and skin infections. In particular, they can be used for oral hygiene: as an antiseptic, anti-inflammatory and analgesic treatment of the gums, mouth and throat, in particular for the treatment of plaque, gingivitis and periodontitis.

The invention is further illustrated by the following examples.

Example 1

A mouthwash was formulated as follows:

Cetylpyridinium chloride 0.050 g

Benzidamine hydrochloride 0.150 g

Glycerol 6,000 g

Ethanol 5,000 g

Sodium saccharin 0.075 g

Ethoxylated hydrogenated castor oil 0.250 g

Blue dye 0.001 g

Yellow dye 0.002 g

Mint flavor 0.100 g

Distilled water to 100 ml

Example 2

Analgesic suckable tablets were prepared from the following components (per tablet):

Cetylpyridinium chloride 1.0 mg

Benzidamine hydrochloride 3.0 mg

Sorbitol 1138.0 mg

Mannitol 300.0 mg

Stecurate of magnesium 40.0 mg

Mint flavor 10.0 mg

Aspartame 8.0 mg

Example 3

An oral spray was formulated as follows:

Cetylpyridinium chloride 0.500 g

Benzidamine hydrochloride 0.150 g

Glycerol 10,000 g

Ethanol 30,000 g

Sodium saccharin 0.100 g

Ethoxylated hydrogenated castor oil 0.250 g

Mint flavor 0.500 g

Distilled water to 100 ml

BIOLOGICAL EVALUATION

The antimicrobial activity of a combination of cetylpyridinium chloride and benzidamine hydrochloride (1: 3 by weight) was compared with that of the individual components in a minimal inhibitory concentration (M.I.C.) assay against a variety of organisms responsible for oral and vaginal infections.

The results were the following (C - cetylpyridinium chloride, B -benzidamine hydrochloride, C B - mixture 1: 3 by weight).

Mieroorganisno M.I.C. (ncg / ml)

C C) B («) C B (")

Peptostreptococcus anaerobius 3.9 750 <0.2 0.7

"magnus 7.8 750 0.9 2.9

Veillonella parvula 7.8 375 1.9 5.9

M II 3.9 375 <0.2 0.7

"alkalescens 7.8 375 1.9 5.9

"spp 7.8 375 1.9 5.9

Lactobacillus acidophilus 7.8 750 0.2 0.7

3.9 750 <0.2 0.7

II H 3.9 750 <0.2 0.7

'' casei 7.8 750 <0.2 0.7

Actinomyces naeslundi 3.9 375 <0.2 0.7

The II 7.8 750 0.2 0.7

'' viscosus 3.9 750 0.2 0.7

«I w 7.8 375 0.2 0.7

"odontolyticus 3.9 375 <0.2 0.7

Propionibacterium acnes 3.9 375 <0.2 0.7

Capnocytophaga gingivalis 7.8 375 1.9 5.9

"ochracea 3.9 750 1.9 5.9

Bacteroides fragilis 3.9 375 <0.2 0.7

The H 3.9 375 <0.2 0.7

Bacteroides oralis 7.8 750 <0.2 0.7

H M 7.8 750 <0.2 0.7

C. albicans 1 3.9 750 3.9 11.7

2 3.9 187 1.9 5.8

Claims (5)

CLAIMS A pharmaceutical composition comprising an anti-inflammatory amount of benzydamine or a benzydamine salt, a highly effective antimicrobial amount of cetylpyridinium chloride and a pharmaceutically acceptable carrier or excipient. 2. Pharmaceutical composition according to claim 1, formulated for topical application. 3. A composition for oral hygiene, which includes an anti-inflammatory amount of benzydamine or a salt of benzydamine, an antimicrobically effective amount of cetylpyridinium chloride and an orally acceptable carrier or excipient. Composition according to any one of claims 1 to 3, wherein the benzidamine salt is benzidamine hydrochloride. Composition according to any one of claims 1 to 4, wherein the ratio of benzydamine or benzidamine salt to antimicrobial agent is from 1: 3 to 3: 1 by weight.